Incyte’s CCR5 Antagonist Has “Meaningful Advantages” Over Pfizer’s Maraviroc, Firm Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Company says it is in active licensing discussions with “probably half a dozen” firms.